Delve into the field of PARP inhibitors, a class that has gained traction in ovarian, breast, and prostate cancers.
Researchers at AACR described the development of a classifier that identified a proportion of tumor samples with HRD that did not have BRCA1/2 mutations.
Precision gene editing is crucial for treating genetic diseases, as it enables targeted correction of specific mutations. A Korean research team has become the first in the world to significantly ...
To meet the urgent need for accessible homologous recombination-deficient (HRD) test options, we validated a laboratory-developed test (LDT) and a functional RAD51 assay to assess patients with ...
Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials Cancers with homologous recombination deficiency (HRD) can ...
Tokyo, Japan – Researchers from Tokyo Metropolitan University have been studying DNA repair by homologous recombination, where the RecA protein repairs breaks in double-stranded DNA by incorporating a ...
Researchers from Tokyo Metropolitan University have been studying DNA repair by homologous recombination, where the RecA protein repairs breaks in double-stranded DNA by incorporating a dangling ...
A new study led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is shedding light on a novel role of breast cancer gene 1 (BRCA1) in tumor suppression.
Cancers with homologous recombination deficiency (HRD) can benefit from platinum salts and poly(ADP-ribose) polymerase inhibitors. Standard diagnostic tests for detecting HRD require molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results